HYPR Financials: Revenue Breakdown, Margins & Competitor Comparison
Hyperfine, Inc. (HYPR) generates 83.4% of revenue from DEVICE sales, with a gross margin of 50.72% but negative operating and net margins. It competes with SKIN and ECOR, with a market cap of $88.36M. Investors assess its performance in the Advanced Medical Equipment & Technology industry.
How this was made
The 30-second read
Why it matters
The disclosed margins and negative operating income suggest ongoing cash‑burn, which may pressure the stock.
Market read
Provides the first public view of HYPR's financial health, useful for valuation updates.
What to watch
Potential upcoming regulatory approvals or contract wins are not discussed but could change the outlook.
Background
Hyperfine, Inc. (HYPR) is a micro‑cap medical device maker reporting its internal financial breakdown.
Ticker impact
The article provides HYPR's latest revenue breakdown, margins and ROE figures, which were not previously public.
Potential modest price adjustment as investors reassess profitability.
Micro‑cap size and limited scale of the numbers limit market impact, but fresh data can trigger short‑term re‑rating.
Market effects
Highlights margin pressure in the advanced medical equipment sector.
Limited to U.S. micro‑cap investors.
Minimal, as the company is small and sector‑specific.
Counterpoint
Despite weak operating margins, the strong gross margin could signal a turnaround if cost controls improve.
Key entities
- companyHyperfine, Inc.
Medical equipment manufacturer (ticker HYPR).
